FILE PHOTO: An ampule of remdesivir is pictured during a news conference
The government said on Tuesday it has approved Gilead Sciences Inc’s antiviral drug remdesivir for emergency use in treating COVID-19 patients.
Remdesivir is the first drug to show improvement in COVID-19 patients in formal clinical trials. It was granted emergency use authorization by the U.S. Food and Drug Administration (FDA) last month and has received approval by Japanese health regulators.
“(Remdesivir) approved on June 1 under emergency use with condition for five dose administration,” the Drugs Controller General of India said in an email statement.
The drugmaker did not immediately respond to an email seeking further details.
As of Tuesday, India has 198,706 cases of coronavirus and has recorded 5,598 deaths, Health Ministry data showed.
Gilead Sciences had on Monday reported that remdesivir showed modest benefit in patients with moderate COVID-19 given a five-day course, while those who received it for 10 days in the study did not fare as well.
European and South Korean authorities are also looking at remdesivir, with South Korean health authorities last Friday saying they would request imports of the drug. Gilead is yet to gain regulatory approval in either market.
On Sept. 3, 2025, China celebrated the 80th anniversary of its victory over Japan by staging a carefully choreographed event…
Since August 20, Jammu and Kashmir has been lashed by intermittent rainfall. Flash floods and landslides in the Jammu region…
The social, economic and cultural importance of the khejri tree in the Thar desert has earned it the title of…
On Thursday, 11 September, the Congress party launched a sharp critique of Prime Minister Narendra Modi’s recent tribute to Rashtriya…
Solar panels provide reliable power supply to Assam’s island schools where grid power is hard to reach. With the help…
August was a particularly difficult month for the Indian Himalayan states of Uttarakhand, Himachal Pradesh and Jammu and Kashmir. Multiple…
This website uses cookies.